Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

LEAD SUPERVISOR: Professor Ladislav Valkovič, Radcliffe Department of Medicine

Co-supervisor: Professor Damian Tyler, Radcliffe Department of Medicine

 

Commercial partner: RAPID Biomedical GmbH, Rimpar, Germany

Breathlessness, fatigue on exertion and exercise intolerance are common features of obesity, type II diabetes and heart failure. Although central (cardiac) metabolic impairment typifies these conditions, peripheral (muscle) metabolic impairment is simultaneously occurring, and its contribution to exercise intolerance is poorly understood. Whilst it seems obvious that skeletal muscle would be a target for therapeutic intervention to improve exercise capacity, there are currently no muscle targeted therapies. As such, improved assessment of skeletal muscle metabolism in these conditions, is an exciting and important target.

Magnetic Resonance Spectroscopy (MRS) is a non-invasive technique capable of assessing tissue chemical composition and metabolic processes in vivo. In particular, proton/hydrogen (1H)-MR provides insight into lipid metabolism and pH buffering through intramyocellular lipids, acetyl-carnitine and carnosine content quantification, respectively. In addition, tissue oxygenation and perfusion can be assessed using 1H-MR Imaging. Mitochondrial metabolism can then be probed using phosphorus (31P)-MRS through the acquisition of phosphocreatine dynamics during and after exercise. In a complementary manner, carbon (13C)-MRS provides insight into glucose metabolism and glycogen production and storage in muscle. Hence, only a combination of 1H-, 31P- and 13C- MRS in one multi-nuclear protocol could provide a comprehensive assessment of the muscle metabolic phenotype.

To effectively combine all three nuclei into one protocol, a novel dedicated triple tuned radio-frequency (RF) coil capable of excitation and acquisition of MR signals at three different frequencies needs to be designed. This constitutes a significant challenge since adding the electronics needed for additional nuclei causes a drop in performance of the coil. Novel efficient decoupling techniques will need to be designed and tested, e.g., using different coil geometries for the different nuclei.

The objectives of this collaborative project are:

1) To design and construct an efficient triple tuned RF coil for comprehensive assessment of muscle metabolism.

2) To phenotype skeletal muscle metabolism in a group of heart failure patients

This will include the design of efficient decoupling (by evaluating different decoupling mechanisms like geometric, capacitive or inductive decoupling), simulations of electromagnetic fields around the new RF coil designs, construction and testing of the new hardware for performance and safety. The final coil design will be optimised for the planned clinical study. The examination protocol would include: i) measurement of intramyocellular lipids, acetyl-carnitine, creatine and carnosine by 1H-MRS, pre and post exercise; ii) interleaved acquisition of 31P and 13C MRS during exercise for assessment of metabolic fluxes and glycogenolysis rates; and iii) interleaved 31P and 1H MR during recovery for mitochondrial metabolism and tissue perfusion assessment. The combination of these metabolic measures will provide an unparalleled insight into muscle metabolism in vivo and will allow identification of an individualized muscle metabolic phenotype. This will be applied in an interventional study of obese heart failure patients enrolled to our successful very low energy diet programme.

The ability to non-invasively define a muscle metabolic phenotype, in parallel to assessment of cardiac metabolism, will ultimately allow us to design muscle targeting therapies for heart failure patients.

Apply using course: DPhil in Medical Sciences

MRC logo